

Anti-GLP-1(1-36)amide (N-terminal-extension specific)**Mouse monoclonal antibody**

Subclass: IgG1/k

CAT. NO.

HYB 011-05

Clone: 9F8

SPECIFICITY HYB 011-05 is specific for the N-terminal region (residues 1-6) of the GLP-1. No cross-reactivity with GLP-1 (7-36) amide or (7-37). HYB 011-05 reacts with the low activity enzyme GLP-1(1-36)amide, but not with either of the activated forms GLP-1(7-36)amide and GLP-1(7-37)amide.

IMMUNOGEN Synthetic peptide

TESTED APPLICATIONS ELISA, WB

SPECIES REACTIVITY (POSITIVE) Human

SPECIES REACTIVITY (NEGATIVE) Not determined

EPITOPE SPECIFICITY Residues 1-6 of GLP-1

PRESENTATION

Content: Available in 200 µL and 1 mL size. 1 mg/mL +/- 15%. See Certificate of Analysis for details.

Preparation: Protein-A purified

Form: Liquid

Solvent: 0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide

Storage: 4-8°C without exposure to light. No precautions necessary during handling.

APPLICATION **ELISA:** HYB 011-05 can be used in ELISA (1).

WB: HYB 011-05 can be used in Western blotting.

TARGET GLP-1 is a peptide hormone of the glucagon family, produced by the L cells of the intestinal mucosa from the same prohormone as glucagon. The active forms are potent stimulators of glucose-dependent insulin secretion. GLP-1 (1-36) amide is an incompletely processed precursor form showing relatively little bioactivity.

REFERENCES 1. Ghiglione M, Uttenthal LO, Koch C (1993) Monoclonal antibodies to glucagon-like peptide-1. Digestion 54:396-397.

CONDITIONS

Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.